📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Arcellx

1.1 - Company Overview

Arcellx Logo

Arcellx

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Products and services

  • ACLX-001: A controllable, bivalent ARC-T cell therapy utilizing a SparX protein that targets BCMA, delivering BCMA-directed activity in relapsed or refractory multiple myeloma
  • ACLX-002: An ARC-SparX platform cell therapy using a SparX protein to target CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
  • Anitocabtagene autoleucel: A CAR-T cell therapy targeting BCMA for treatment of relapsed or refractory multiple myeloma, currently in a Phase 1 study.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Arcellx

Tectonic Therapeutics Logo

Tectonic Therapeutics

HQ: United States Website
  • Description: Provider of GPCR-targeted biologic drug discovery and development via its GEODe platform, with clinical programs including TX45, a therapeutic protein in Phase 1B trials for Group 2 Pulmonary Hypertension in heart failure with preserved ejection fraction, and an Fc-relaxin fusion targeting the RXFP1 receptor.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tectonic Therapeutics company profile →
Corvus Pharmaceuticals Logo

Corvus Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical solutions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Corvus Pharmaceuticals company profile →
Vical Logo

Vical

HQ: United States Website
  • Description: Provider of biopharmaceutical product research and development based on its patented DNA delivery technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vical company profile →
InDex Pharmaceuticals Logo

InDex Pharmaceuticals

HQ: Sweden Website
  • Description: Provider of clinical-stage biopharmaceutical immunotherapy R&D based on a toll-like receptor (TLR) platform, discovering and developing DNA-based immunomodulatory sequence (DIMS) drugs to treat diseases in therapeutic areas including inflammation and cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full InDex Pharmaceuticals company profile →
Takara Bio Logo

Takara Bio

HQ: Japan Website
  • Description: Provider of life science reagents, kits, gene therapy solutions, and contract biology development services. Develops, manufactures, and distributes products under the Takara, Clontech, and Cellartis brands, including SMART cDNA synthesis kits for NGS and other applications, and high-performance qPCR/PCR reagents such as Takara Ex Taq and Takara LA Taq.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Takara Bio company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Arcellx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Arcellx

2.2 - Growth funds investing in similar companies to Arcellx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Arcellx

4.2 - Public trading comparable groups for Arcellx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Arcellx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Arcellx

What does Arcellx do?

Arcellx is a provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Who are Arcellx's competitors?

Arcellx's competitors and similar companies include Tectonic Therapeutics, Corvus Pharmaceuticals, Vical, InDex Pharmaceuticals, and Takara Bio.

Where is Arcellx headquartered?

Arcellx is headquartered in United States.

How many employees does Arcellx have?

Arcellx has 1,000 employees 🔒.

When was Arcellx founded?

Arcellx was founded in 2010 🔒.

What sector and industry vertical is Arcellx in?

Arcellx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Arcellx

Who are the top strategic acquirers in Arcellx's sector and industry

Top strategic M&A buyers and acquirers in Arcellx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Arcellx?

Top strategic M&A buyers groups and sectors for Arcellx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Arcellx's sector and industry vertical

Which are the top PE firms investing in Arcellx's sector and industry vertical?

Top PE firms investing in Arcellx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Arcellx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Arcellx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Arcellx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Arcellx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Arcellx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Arcellx?

The key public trading comparables and valuation benchmarks for Arcellx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Arcellx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Arcellx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Arcellx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Arcellx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Arcellx's' sector and industry vertical?

Access recent funding rounds and capital raises in Arcellx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Arcellx

Launch login modal Launch register modal